Novel aniline derivative, pharmaceutical composition containing same, and use thereof
AssigneeKissei Pharmaceutical Co., Ltd.
InventorsHitoshi Inoue, Kohsuke Ohno, Tetsuya Nakamura, Yusuke Ohsawa
Life of this patent
Estimating the term…
Loading patent…
AssigneeKissei Pharmaceutical Co., Ltd.
InventorsHitoshi Inoue, Kohsuke Ohno, Tetsuya Nakamura, Yusuke Ohsawa
Estimating the term…
[Problem] The present invention provides a novel compound having an S1P1 receptor antagonistic activity. [Solution] The present invention provides a compound represented by the general formula (I): (in the formula, Rl, R2 and R3 are each a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group or the like, R4 is a C1-6 alkyl group or the like, R5 is a C1-6 alkyl group or the like, R6 is a C1-6 alkyl group or the like, R7 is a hydrogen atom, a halogen atom, a C1-6 alkyl group or the like, R8 is a halogen atom, a C1-6 alkyl group, a halo C1-6 alkyl group, a C1-6 alkoxy group or the like, and R9 is a hydrogen atom or a C1-6 alkyl group.) or a pharmaceutically acceptable salt thereof, a pharmaceutical compositions containing same, and use thereof. The compounds of the present invention have an excellent S1P1 receptor antagonistic activity and therefore are useful as an agent for the treatment or prevention of antoimmune diseases and the like.
1-16. (canceled)
A method of treating a disease mediated by S1P1 receptor in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound represented by the general formula (I):
A method of treating a disease mediated by S1P1 receptor in a subject, said method comprising administering to said subject a therapeutically effective amount of 1-(5-{1-[(4-Chloro-3-trifluoromethylphenyl)(ethyl)amino]ethyl}-2-methylbenzyl)azetidine-3-carboxylic acid or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.